- Home
- PHAT vs CII Comparison
PHAT vs CII Comparison
Compare PHAT & CII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PHAT | CII |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 963.2M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | PHAT | CII |
|---|---|---|
| Price | $12.78 | $23.18 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $17.33 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 78.8K |
| Earning Date | 03-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.17% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $147,190,000.00 | N/A |
| Revenue This Year | $221.87 | N/A |
| Revenue Next Year | $80.37 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 460.30 | N/A |
| 52 Week Low | $2.21 | $16.76 |
| 52 Week High | $18.31 | $19.81 |
Technical Indicators
Market Signals| Indicator | PHAT | CII |
|---|---|---|
| Relative Strength Index (RSI) | 38.22 | 48.01 |
| Support Level | $12.22 | $22.39 |
| Resistance Level | $14.53 | $23.48 |
| Average True Range (ATR) | 0.85 | 0.31 |
| MACD | -0.12 | -0.01 |
| Stochastic Oscillator | 23.22 | 69.70 |
Price Performance
Historical ComparisonAbout PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About CII Blackrock Capital and Income Fund Inc.
Blackrock Enhanced Cap&Inc Fund, Inc is a closed-end management investment company. Its objective is to provide total return through a combination of current income and capital appreciation. The trust seeks to achieve its investment objective by investing a majority of its total assets in a portfolio of equity securities of U.S. and foreign issuers.